Key facts
- New Lantern’s last known valuation is $74.0M.
- It has raised $22.6M; the latest was Early Stage VC ($19.0M) in Nov 2024.
- Notable investors include Gaingels, SV Angel, Menlo Ventures, Gokul Rajaram, Guillermo Rauch — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for New Lantern
- ·The full record, as it builds
Funding rounds
No funding rounds for New Lantern are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About New Lantern
Developer of an AI-powered diagnostic imaging platform intended for healthcare providers. The company's platform automates radiology measurements, streamlines disease evolution analysis, and integrates technologists' notes directly into reports while generating personalized impressions tailored to the clinical context, enabling healthcare professionals to improve efficiency, reduce manual workload, and enhance diagnostic accuracy through advanced cloud-native technology.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2021
- Employees
- 19
- Website
- newlantern.ai/
- Ownership
- Privately Held (backing)
New Lantern doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in New Lantern shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on New Lantern in its N-PORT filings yet. We sweep new filings monthly.